INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer and the third most common cause of cancer death in men in the Western world. [1] [2] [3] [4] Although many men have indolent diseases that can be cured with localized therapies, a significant minority of men will relapse and eventually progress to castrationresistant PCa. The majority of lethal PCa is due to the spread through castration-resistant metastasis. 5, 6 Alongside the long-established treatments for PCa including prostatectomy, radiotherapy and androgen deprivation, there is currently a list of therapies that have been approved recently or are still in development that target various pathogenic processes shown to be important for PCa progression-for example, androgen related, targeting several signalling pathways (PI3K-Akt-mTOR, IGFIR, hedgehog), immunomodulators and vaccines, epigenetic modifiers as well as bone-specific treatments. [7] [8] [9] Angiogenesis has been described as being essential for tumour growth. 10 It is today recognized as one of the hallmarks of cancer 11 and subject to intense investigations for therapeutic control. There are many studies that have suggested angiogenesis to be important in PCa: vascular endothelial growth factor (VEGF) is expressed at high levels in human PCa cell lines; 12, 13 urine and plasma levels of VEGF are increased in advanced stages of PCa; [14] [15] [16] and microvessel density correlates with PCa metastasis and Gleason score. 17 However, all of these studies show correlations and do not demonstrate causality, that is, angiogenesis driving the PCa progression and spread or is it, for example, an associated phenomenon resulting from the hypoxic environment of tumour growth? The most definitive answer to this question may come only from studies assessing the efficacy of anti-angiogenic therapy in PCa patients.
On the basis of this rationale, several multi-centre studies have been initiated using combinations of adjuvant anti-angiogenic therapies that target angiogenesic molecules, for example, VEGF or VEGFRs, angiopoetins (reviewed in Mukherji et al. 18 ). To date, the results are discouraging for angiogenesis-specific agents-for example, a phase III study recently completed that used bevacizumab (humanized antibody against VEGF) in addition to docetaxel and prednisone, but failed to show a significant improvement in overall survival. 19 Several other phase III studies of anti-VEGF-based strategies have failed to improve survival in unselected patients with metastatic castration-resistant prostate cancer, including sunitinib (a VEGF/PDGF tyrosine kinase inhibitor) and aflibercept (VEGF trap). 18 Several explanations have been advanced for the failure of these studies, including excess treatment-related toxicities, lack of patient selection and dilution of treatment effect given the notorious heterogeneity of PCa at every level (clinical, histopathological or molecular). 19 More than 10 years ago, a 3′ alternative splicing event in the terminal exon of VEGF-A pre-mRNA was described that does not change the number of amino acids in the VEGF protein but rather the sequence of the last six amino acids. 20 This gives rise to a family of VEGF isoforms (VEGF xxx b, with the dominant isoform VEGF 165 b) that act as antagonist/partial agonist to the main VEGF receptor (VEGFR2). 21 VEGF 165 b has been shown in several studies to be anti-angiogenic. [22] [23] [24] An alternative hypothesis for the failure of anti-angiogenic therapies in PCa, which has not been considered thus far, is that the above-mentioned studies use treatments that inhibit all VEGF isoforms regardless of their pro/anti-angiogenic potential and/or do not select patients based on these VEGF isoforms. Indeed, it has been shown, for example, that pro/anti-angiogenic VEGF isoform balance can predict response to anti-VEGF antibodies in animals 25 and humans in colon carcinoma. 26 We recently described an essential pathway that regulates the choice of pro/anti-angiogenic splicing isoforms, which involves the serine-arginine protein kinase 1 (SRPK1) and splicing factor SRSF1 27, 28 in renal epithelial cells and in colon carcinoma. We have shown that knockdown (KD) of SRPK1 in colon adenocarcinoma cells (LS174t) increases the levels of anti-angiogenic splicing isoform VEGF 165 b and inhibits tumour growth in a xenograft model. SRPK1 is a kinase, a class of proteins that have proven recently to be exceptional targets for oncology therapeutic development. Our previous findings suggested that selective SRPK1 inhibitors could act as anti-angiogenic agents and novel cancer treatments in cancers where SRPK1 was active.
The aim of this study was therefore to assess whether the SRPK1-SRSF1 axis is upregulated in PCa human samples and cell lines and, if so, test the hypotheses that (i) manipulation of VEGF 165 b levels and SRPK1 axis in PCa cells is able to decrease tumour growth in xenografts models and (ii) this is primarily due to an effect on VEGF splicing. The ultimate goal was to provide basic proof-of-principle studies for use of SRPK1 inhibitors in PCa treatment.
RESULTS

SRPK1 and SRSF1 expressions in human PCa
In a previous study, 23 we reported that the anti-angiogenic VEGF 165 b splice isoform is strongly downregulated in malignant human prostate tissue compared with benign tissue, based on transurethral sections of the prostate samples. The choice of pro/anti-angiogenic VEGF isoforms has been shown in colonic and renal epithelial cells to be under the control of SRSF1 and SRPK1, and KD of SRPK1 switched splicing from VEGF 165 to VEGF 165 b in colon carcinoma cells (LS174t). 27 Here we show that in a mouse subcutaneous xenograft model of PCa, using human PC-3 cells, intraperitoneal administration of rhVEGF 165 b is also able to decrease prostate tumour growth in a similar manner to the anti-VEGF antibody bevacizumab and this is associated with a decrease in microvessel density in tumours (Supplementary Figure 1 ). We therefore considered that the expression level of SRPK1 and SRSF1 in human PCa tissue may be able to control VEGF-A 165 b expression and thus be a potential target for therapy.
Samples from 17 patients with radical prostatectomy were immunostained for SRPK1 and SRSF1 ( Figure 1 ). Staining intensities were scored by a urological pathologist in benign areas, prostatic intraepithelial neoplasia (PIN) lesions as well as malignant parts of the gland. SRPK1 staining ( Figure 1a ) was significantly increased in both PIN and malignant regions compared with benign areas of the samples (Figure 1b ). SRSF1 staining ( Figure 1c ) was increased in malignant but not PIN lesions ( Figure 1d ). SRPK1-KD results in a splicing switch from pro-to anti-angiogenic VEGF isoforms in PCa cells SRPK1 expression was assessed in several PCa cell lines (PC-3, DU145 and LNCaP) in comparison with normal prostate epithelial cells by quantitative reverse transcription PCR (qRT-PCR; Figure 2a ). The highest expression was present in PC-3 cells. At the protein level, SRPK1 was also higher in PC-3 and DU145 cells when compared with LNCaP ( Figure 2b ). This heterogeneity was reflective of PCa samples where SRPK1 is increased in~50% of patients ( Figure 1B ). We therefore used PC-3 in further studies to understand the role of SRPK1 in those PCa's with increased expression.
To establish whether the SRPK1-VEGF splicing regulation was present in PC-3 cells, we generated a stable KD of SRPK1. PC-3 cells were transduced with lentivirus-containing shRNAi to SRPK1 or scrambled shRNAi, selected in puromycin for 3 weeks and mRNA and protein extracted. The extent of knockdown was To determine whether SRPK1-KD in PC-3 cells influenced SR protein expression and/or phosphorylation, western blot analysis was performed. Supplementary Figure 4 shows that expression of different SR proteins was not affected but there was a pronounced decrease in phosphorylation in SRSF1, 2 and 5 in KD cells compared with controls.
SRPK1-KD does not affect cell growth, proliferation, invasion and migration of PC-3 cells in vitro
SRPK1 is a kinase with multiple SR proteins as targets, which in turn affect splicing of several genes. 28 Moreover, PC-3 cells express VEGFR2 and 1 as well as neuropilin 1 (Supplementary Figure 5 ), which potentially could respond to different VEGF ligands. Thus, SRPK1-KD could result in differential autocrine effects of VEGF isoforms on PC-3 cells that may affect their ability to proliferate, invade and migrate. Cell-counting assays showed no significant difference at any time point between the growth rates of PC-3 SRPK1-KD compared with control cells at the same time point (P40.05, two-way analysis of variance (ANOVA), n = 3 experiments of three independent replicates; Figure 3a ). Cell proliferation was also assessed with Ki-67 staining, and again there was no significant difference between the proliferation rates of PC-3 SRPK1-KD and control cells (P40.05, two-way ANOVA, n = 2 experiments of three independent replicates; Figure 3b ). The potential of cells to migrate and invade was determined using a Matrigel invasion assay. There was no significant difference in the number of cells migrating between PC-3 SRPK1-KD and control (CTRL) groups (P = 0.06, unpaired t-test; Figure 3c ). The same experiment was repeated using a different migration set-up-Fluoroblock membranes (BD Biosciences, Franklin Lakes, NJ, USA) with the same result (data not shown). Furthermore, no difference in migration velocities between PC-3 cells with SRPK1-KD and control cells were observed in a scratch-wound assay (P40.05, two-way ANOVA, n = 3; Figure 3d ).
These data taken together suggest that SRPK1-KD does not result in an effect on PC-3 cells by regulating VEGF or other gene splicing, which would influence their rate of growth, proliferation, migration or invasion in vitro.
SRPK1-KD reduces subcutaneous PC-3 tumour growth in vivo through inhibition of angiogenesis in a manner dependent on VEGF splicing
As SRPK1-KD induced a splicing switch towards VEGF antiangiogenic isoforms, we investigated whether this would affect the rate of tumour growth in vivo. PC-3 SRPK1-KD or control cells (1x10 6 ) were injected subcutaneously in the flank of male nude mice and tumour volume was monitored. There was a significant decrease in tumour growth rate in PC-3 SRPK1-KD mice compared with control (n = 9), *P o0.05, two-way ANOVA (Figure 4a and examples of tumour growth in mice in Figure 4b ).
At day 29, the mice were culled and RNA from the tumour samples was subjected to qRT-PCR to examine SRPK1 expression (normalized to total amount of RNA). There was a significant difference in the mean SRPK1 expression between the two groups (***P o0.001, t-test) and there was a significant positive correlation of SRPK1 copy number and tumour volume (***P o0.001, r = 0.7377, Spearman rank correlation test; Supplementary Figure 6 ).
PC-3 SRPK1-KD or control tumour samples were stained for CD31 endothelial cell marker and the blood vessel density counted. There was a significant reduction in blood vessel density in PC-3 SRPK1-KD mice compared with control (*P o0.05, unpaired t-test; Figures 4c and d) . Western blot analysis of protein extracts from tumours shows that SRPK1-KD corresponds to a decrease in VEGF levels (see examples in Figure 4e ).
These data taken together suggest that the main effect through which SRPK1 causes a decrease in tumour growth is by affecting angiogenesis through a switch in VEGF splicing isoforms from pro-angiogenic to anti-angiogenic. To more clearly test this hypothesis, we designed a VEGF-rescue experiment in vivo in which we asked whether VEGF 165 complementary DNA (cDNA) overexpression driven by a VEGF promoter (which would mimic endogenous VEGF but be insensitive to alternative splicing) could rescue the tumour growth in SRPK1-KD cells.
SRPK1-KD or control cells were transfected with a plasmid containing the VEGF 165 cDNA under the control of the VEGF promoter. SRPK1-KD did not affect VEGF promoter activity in PC-3 cells, as assessed in vitro using a luciferase reporter plasmid driven by the endogenous VEGF promoter sequence ( Supplementary  Figure 7) . One million PC-3 SRPK1-KD/VEGF 165 and CTRL KD/VEGF 165 cells were injected subcutaneously in the flank of male nude mice and tumour volume was monitored. As a control, 1x10 6 PC-3 SRPK1-KD/pCDNA3 and CTRL/pCDNA3 cells (transfected with empty plasmid) were injected in parallel. The ability of the cell to generate VEGF 165 (circles) significantly rescued the inhibition of tumour growth in the presence of SRPK1-KD (filled symbols, P o0.01, two-way ANOVA). SRPK1-KD thus had no effect on cells that could express VEGF 165 under the control of the VEGF promoter (circles, P40.1, two-way ANOVA) but did in the cells expressing multiple isoforms of VEGF (squares, P o 0.05, two-way ANOVA). *P o 0.05, **P o0.01 compared with SRPK1-KD-VEGF 165 (Figures 5a and b) .
SRPK1 levels were decreased in tumours grown from SRPK1-KD cells compared with control cells in both sets with either expression of empty vector plasmid (Figure 6a Small-molecule inhibitors of SRPK1 are able to switch VEGF splicing in vitro in PC-3 cells and decrease tumour growth in vivo in an orthotopic PCa mouse model We have previously shown that several SRPK1 inhibitors are able to switch VEGF splicing towards the anti-angiogenic isoforms in vitro and have anti-angiogenic effects in vivo in different systems. 27, 29, 30 As SRPK1-KD is able to slow tumour growth in PC-3 xenografts, we enquired whether chemical inhibition of SRPK1 may have similar results in a therapeutic proof-of-principle experiment.
To examine changes in SR protein phosphorylation, PC-3 cells were treated with SRPK1 inhibitors followed by EGF, previously shown to induce SRPK1-dependent SR activation. 31 Two different inhibitors were used at 10 μM; SPHINX and SRPIN340, which have different selectivities for SRPK1. 30 After 30 min pre-treatment with the inhibitors, cells were incubated with 100 ng/ml EGF for an hour and protein extracted. Immunoblot analysis for phosphorylated SR proteins revealed a 115% upregulation of phosphoSRSF1/2 and 90% upregulation of pSRSF5, but no change in pSRSF6 on EGF treatment, compared with control-treated cells (dimethylsulphoxide 0.02%). However, prior treatment with the inhibitors resulted in reduction of EGF-dependent SRSF1/2 phosphorylation (to 14 and 1% by SRPIN340 and SPHINX, respectively) but not SRSF5 (60 and 50% increase, respectively; Figure 7a ). This was confirmed in a different experimental design where phospho-SR proteins were immunoprecipitated with mAb 104 antibody followed by immunoblotting with SRSF1 antibody (Supplementary Figure 8) .
The effect of SPHINX on VEGF protein isoform expression was also examined (Figure 7b ). There was a significant downregulation of VEGF 165 after treatment with 5 and 10 μM SPHINX compared with control (P = 0.020; one-way ANOVA, *P o0.05). However, at 20 μM treatment, the reduction of the pro-angiogenic isoform was lost and no difference was observed compared with control group (P40.05, one-way ANOVA). Subsequently, the expression of VEGF 165 b isoform was examined using an antibody against all VEGF xxx b isoforms. As shown in Figure 7b , there was a significant effect on VEGF 165 b expression on treatment with the smallmolecule inhibitor. On the basis of these results and to examine the hypothesis that SRPK1 is a therapeutic target for PCa, we used the orthotopic PCa model to assess the effect of SPHINX on tumour growth. PC-3 red fluorescent protein (RFP)-tagged cells (1 × 10 6 ), resuspended in 20 μl of sterile phosphate-buffered saline, were injected into the prostate gland of male nude mice. The use of PC-3 RFP-expressing cells enabled the detection and quantification of tumours, beneath the skin, using the IVIS Lumina system (Perkin-Elmer, Waltham, MA, USA) (examples of fluorescence detection are shown in Figure 7c ). Once tumours reached~4-5 × 10 10 photons per second (p/s), mice were treated. Two treatment groups were used: intraperitoneal injections of 20 μg SPHINX or saline three times a week. In the control-treated groups, the fluorescence signal increased. The fluorescence was quantitated as shown in Figure 7d . It should be noted that the images shown in Figure 7b show both direct and reflected light collected from the cone emitting from the fluorescent source, and so do not reflect metastasis, but an increased size of primary tumour. This was confirmed when the mice were killed and dissected and no dissemination was seen but a large primary growth. Treatment with SPHINX resulted in a significant inhibition of tumour growth compared with saline group (*P o 0.05 and **P o 0.01, two-way ANOVA; Figure 7d ).
DISCUSSION
Angiogenesis is an essential process through which growing tumours are able to form blood vessels and obtain necessary nutrients. However, tumour cells can be very heterogeneous in their metabolism and therefore their dependence on oxygen and nutrients, with some of the most aggressive cancer cells being able to survive and proliferate with poor energy supplies. 11 Although correlation of tumour growth and progressive phenotype with microvessel density may provide clues for the importance of angiogenesis in cancers, including PCa, the ultimate proof of how reliant cancer growth is on angiogenesis comes from studies in which angiogenesis inhibitors are used. The discouraging results of recent trials using anti-angiogenic therapies on patients with advanced PCa may be explained, at least in part, by an incomplete knowledge of the regulation and biology of VEGF (the main determinant of angiogenesis), which most of these studies are set to inhibit. These studies use compounds that inhibit all forms of VEGF (either directly, for example, bevacizumab, or indirectly through receptor inhibition, for example, sunitinib) without taking into account the diversity of VEGF molecules and their functions (that is, some of them are naturally anti-angiogenic) acquired through numerous levels of gene regulation, including alternative splicing. Only recently a few studies on patients with various cancers (but not PCa) have taken into account the response to bevacizumab therapy depending on various VEGF isoforms (reviewed in Lambrechts et al. 32 ).
We have shown previously that the kinase SRPK1 is one of the most important regulators of the VEGF 165 /VEGF 165 b splicing switch (through modulation of the SR protein family splicing factor SRSF1) and that SRPK1-KD in colon carcinoma cell line LS174t inhibits tumour growth by inhibiting angiogenesis. 27 Several small-molecule inhibitors for SRPK1 exist (for example, SRPIN340 33 and SPHINX 30 ).
SRPK1 has been reported to be upregulated in several cancers, for example, breast, colon and pancreas; 34 ovarian; 35 non-small cell lung carcinoma; 36 or hepatocellular carcinoma. 37 Here we show that SRPK1 expression was much higher in samples from patients with malignant PCa compared with normal prostate tissue (Figure 1a ). This correlates with data previously reported that malignant prostate tissue expresses the pro-angiogenic VEGF isoform while normal tissue shows a combination of both isoforms. 23 Interestingly, SRPK1 expression was also significantly higher in PIN lesions when compared with benign tissue. This may suggest that activation of SRPK1 and therefore promotion of proangiogenic splicing in VEGF might be an early event in development of PCa and moreover, indicates that angiogenesis may be a causal phenomenon that drives PCa progression and not a consequence of an increasing hypoxic environment during tumourigenesis. However, it was also interesting that SRPK1 was not raised in all PCa's ( Figure 1b) , and that some PCa lines (for example, LNCaP) do not have high SRPK1 expression. These cells may have other splicing regulatory pathways that are altered. Furthermore, SRSF1 expression (which is downstream of SRPK1) was significantly increased in malignant but not in PIN lesions (Figure 1c) , which may underlie the progressive and sequential activation of SRPK1-SRSF1 axis in PCa. It is not yet known whether SRSF1 expression follows aggressiveness in cancer cell lines, but it would be interesting to compare this across PCa cell lines. Moreover, other splice factors like SRSF5 and SRSF6 have been shown to be involved in splicing of VEGF at the terminal exon and future assessments of expression of these factors in human samples will hopefully provide a comprehensive picture of SRPK1-SR axis in PCa.
We further show that SRPK1-KD switches the balance of the main VEGF splicing isoform towards the anti-angiogenic one in PC-3 cells ( Figure 2 ) and inhibits tumour growth in PC-3 xenografts with associated decrease in microvessel density (Figure 4 ). It did this by reducing the amount of VEGF-A 165 a, that is, switching from active to repressed proximal splicing. Of interest, the switch in splicing at the protein level indicated a higher level of VEGF-A 165 b protein than that suggested by the PCR. This could be due to differential translation, but is likely also to be due to competition in amplification when two transcripts are generated from the same target sequence. VEGF-A 165 competes with VEGF-A 165 b for primer annealing, resulting in over-representation of the most common isoform. Therefore, a small increase in the PCR signal could result from a large increase in the relative abundance. 38 SRPK1 has multiple targets beside SRSF1 and its knockdown has been shown to affect other hallmarks of cancer in different cancers (see references above). However, SRPK1-KD in PC-3 cells does not have any autocrine effect on cell growth, proliferation, migration and invasion in vitro (Figure 3 ), a feature that is different from cell lines representative for other types of cancers. Moreover, expression in SRPK1-KD cells of splicing-insensitive VEGF cDNA driven by VEGF endogenous promoter rescues tumour growth ( Figure 5 ). These data taken together strongly suggest that the main reason for inhibition of tumour growth in PC-3 cells with SRPK1-KD is the effect on angiogenesis and is unlikely to be related to other hallmarks of cancer. In addition, SRPK1-KD has no influence on the VEGF promoter (see Supplementary Figure 7 ), providing additional support for the hypothesis that the SRPK1-KD effect is mediated through the switch in VEGF splicing isoforms.
Finally, in a therapeutic proof-of-principle experiment, we show that SRPK1 inhibitors are able to inhibit phosphorylation of relevant SR proteins and switch VEGF splicing in vitro (Figures 7a  and b ). One of the inhibitors, SPHINX, decreases tumour growth when administered repetitively intraperitoneally in a mouse model of orthotopic PCa using PC-3 cells (Figure 7c ).
In conclusion, our study identifies SRPK1 as a key molecule in regulating the balance of VEGF splice isoforms in PC-3 cells whose inhibition results in decrease in tumour growth due to the effect on angiogenesis. This encourages novel studies for the potential use of small-molecule inhibitors of SRPK1 in PCa as antiangiogenic therapy.
MATERIALS AND METHODS
Cell culture PC-3 and DU145 cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) and LNCap cells in RPMI1640 with 10% fetal bovine serum (FBS) and antibiotics. PC-3, LNCaP and DU145 cells were purchased from ATCC (Manassas, VA, USA); cells were authenticated by Short Tandem Repeat Profiling at Identicell, Denmark (08/2011). Primary prostate epithelial cells were purchased from Lonza (Basel, Switzerland), not authenticated and cultured in PrEBM medium (Lonza). SRPK1-KD cell sublines were generated by transduction of cell lines with lentivirus-encoding shRNAi to SRPK1 (Dharmacon, Lafayette, CO, USA). Transduced PC-3 cells were transfected with VEGF 165 plasmid or empty pcDNA3 using Fugene HD (Promega, Madison, WI, USA) and selected in Geneticin (Life Technologies, Carlsbad, CA, USA).
Proliferation assay
Cells (10 5 ) seeded in six-well plates were counted after 24, 48 and 72 h using a haemocytometer. For Ki-67 proliferation assay, 10 5 cells were serum starved for 8 h. Twenty-four, 48 and 72 h after starvation, cells were fixed with 4% paraformaldehyde and incubated with anti-Ki67 antibody 1:100 (Abcam, Cambridge, UK), overnight at 4°C. Alexa-fluor 488 goat antirabbit antibody (Life Technologies) (1:750) was used as secondary. The proliferation potential of cells was measured on Image J (NIH, Bethesda, MD, USA) by calculating the total nuclear intensity of Ki-67 and normalizing to total nuclear area.
Migration-invasion assays
Scratch-wound assay: 1-mm-thick line was scratched off the cell monolayer using a sterile tip. The migration potential of cells was determined by measuring the distance covered by cells (Image J) during 24 or 48 h to the middle of the scratch wound. For the migration-invasion assay, 50 μl of matrigel (Sigma, St Louis, MO, USA) was added into each chamber Figure 6 . Expression analysis by western blot of SRPK1 (a) and VEGF (b) levels in the four sets of tumours from the rescue experiment. SRPK1 inhibition in prostate cancer A Mavrou et al (Millipore, Darmstadt, Germany) before plating the cells. Cells (5x10 4 ), resuspended in DMEM containing 2% FBS, were then plated onto the chambers. DMEM with 10% FBS was added in the wells of the plates to generate a serum gradient. After incubation, inserts were fixed in 4% paraformaldehyde and stained with Hoechst. To assess invasion potential, five fields of view were taken at × 20 magnification and cells counted.
RNA extraction, reverse transcription and PCR
TRIzol (Invitrogen, Carlsbad, CA, USA) was used to extract RNA from all cells and tumours. One-two μg of RNA was used for first-strand cDNA synthesis. PCR was performed using primers listed in Supplementary Table 1 .
Protein studies
Cell lines and tumour samples were lysed in RIPA buffer, containing protease inhibitors. For VEGF ELISA, the Pan-VEGF and VEGF xxx b Elisa kits (R&D, Minneapolis, MN, USA) were used. For western blot, mouse anti-SRPK1 (BD Biosciences, Santa Cruz, CA, USA), rabbit anti-panVEGF, mouse anti-VEGF xxx b (A56/1) or goat anti-β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.
In vivo models
For heterotopic xenografts, 1 × 10 6 transduced and/or transfected PC-3 cells resuspended in 100 μl of phosphate-buffered saline were injected subcutaneously in male nude mice. Tumours were measured with a caliper every 3 days and tumour volume was calculated according to the formula: [(length+width)/2] × length × width. When the first tumour reached 16 mm in diameter, mice were culled, tumours were excised, half homogenized in Trizol for RNA extraction and the other half embedded in paraffin for staining. For orthotopic implantation, RFP-tagged PC-3 cells (AntiCancer Inc., San Diego, CA, USA) 39 were surgically injected into the prostate of nude mice and tumour growth monitored using a Xenogen IVIS device.
Immunohistochemistry
Paraffin-embedded samples were cut in 5-7 mm sections and standard immunohistochemistry protocols were used. For vessel density, rabbit polyclonal CD31 antibody (Abcam) and DAB kit (Vector Laboratories, Burlingame, CA, USA) were used for colour development. For SRPK1 immunohistochemistry, rabbit anti-SRPK1 primary antibody (Sigma) was used at 1 μg/ml concentration and Fast-Red solution (Sigma) for colour development.
Blood vessel density
Two sections from each tumour were analysed using a Nikon E400 microscope (Nikon, Tokyo, Japan) (×40 objective). Blood vessels were identified and counted based on CD31-positive staining, and mean number of blood vessels per field of view (three fields of view per section) was calculated.
Human sample scoring
Scoring was done blindly by a histopathologist (JO) according to the intensity of staining-0 for no staining; 1 for weak; 2 for moderate; and 3 for strong staining. 
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